174 related articles for article (PubMed ID: 31685261)
21. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
[TBL] [Abstract][Full Text] [Related]
22. Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.
Dobes P; Podhorec J; Coufal O; Jureckova A; Petrakova K; Vojtesek B; Hrstka R
Oncol Rep; 2014 Oct; 32(4):1695-702. PubMed ID: 25051299
[TBL] [Abstract][Full Text] [Related]
23. Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1.
van der Post RS; Vogelaar IP; Manders P; van der Kolk LE; Cats A; van Hest LP; Sijmons R; Aalfs CM; Ausems MG; Gómez García EB; Wagner A; Hes FJ; Arts N; Mensenkamp AR; van Krieken JH; Hoogerbrugge N; Ligtenberg MJ
Gastroenterology; 2015 Oct; 149(4):897-906.e19. PubMed ID: 26072394
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population.
Meiss AE; Thomas M; Modesitt SC; Ring KL; Atkins KA; Mills AM
Hum Pathol; 2018 Dec; 82():20-31. PubMed ID: 29958926
[TBL] [Abstract][Full Text] [Related]
25. The horizon of precision medicine in breast cancer: fragmentation, alliance, or reunification?
Andre F; Vicier C; Delaloge S
Am Soc Clin Oncol Educ Book; 2014; ():e5-10. PubMed ID: 24857146
[TBL] [Abstract][Full Text] [Related]
26. Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.
Christgen M; Bartels S; Luft A; Persing S; Henkel D; Lehmann U; Kreipe H
Virchows Arch; 2018 Nov; 473(5):577-582. PubMed ID: 30094493
[TBL] [Abstract][Full Text] [Related]
27. Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE.
LeNoue-Newton ML; Chen SC; Stricker T; Hyman DM; Blauvelt N; Bedard PL; Meric-Bernstam F; Punglia RS; Schrag D; Lepisto EM; Andre F; Smyth L; Dogan S; Yu C; Wathoo C; Levy M; Eli LD; Xu F; Mann G; Lalani AS; Ye F; Micheel CM; Arnedos M
Clin Cancer Res; 2022 May; 28(10):2118-2130. PubMed ID: 35190802
[TBL] [Abstract][Full Text] [Related]
28. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.
Boyault S; Drouet Y; Navarro C; Bachelot T; Lasset C; Treilleux I; Tabone E; Puisieux A; Wang Q
Breast Cancer Res Treat; 2012 Feb; 132(1):29-39. PubMed ID: 21512767
[TBL] [Abstract][Full Text] [Related]
29. Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.
Lien HC; Chen YL; Juang YL; Jeng YM
Breast Cancer Res Treat; 2015 Apr; 150(2):447-55. PubMed ID: 25773929
[TBL] [Abstract][Full Text] [Related]
30. Concordance of genomic alterations between primary and recurrent breast cancer.
Meric-Bernstam F; Frampton GM; Ferrer-Lozano J; Yelensky R; Pérez-Fidalgo JA; Wang Y; Palmer GA; Ross JS; Miller VA; Su X; Eroles P; Barrera JA; Burgues O; Lluch AM; Zheng X; Sahin A; Stephens PJ; Mills GB; Cronin MT; Gonzalez-Angulo AM
Mol Cancer Ther; 2014 May; 13(5):1382-9. PubMed ID: 24608573
[TBL] [Abstract][Full Text] [Related]
31. Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer.
Kaur P; Porras TB; Ring A; Carpten JD; Lang JE
Sci Rep; 2019 Feb; 9(1):1482. PubMed ID: 30728399
[TBL] [Abstract][Full Text] [Related]
32. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
33. Genotype-Phenotype Correlations in Breast Cancer.
Marotti JD; Schnitt SJ
Surg Pathol Clin; 2018 Mar; 11(1):199-211. PubMed ID: 29413657
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive genomic profiling of malignant phyllodes tumors of the breast.
Nozad S; Sheehan CE; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon S; Schrock AB; Hirshfield KM; Ali N; Ganesan S; Ali SM; Miller VA; Stephens PJ; Ross JS; Chung JH
Breast Cancer Res Treat; 2017 Apr; 162(3):597-602. PubMed ID: 28210881
[TBL] [Abstract][Full Text] [Related]
35. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ
Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147
[TBL] [Abstract][Full Text] [Related]
36. Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers.
Santa-Maria CA; Kruse M; Raska P; Weiss M; Swoboda A; Mutonga MB; Abraham J; Jain S; Nanda R; Montero AJ
Breast Cancer Res Treat; 2017 Nov; 166(1):179-184. PubMed ID: 28752189
[TBL] [Abstract][Full Text] [Related]
37. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
Cejalvo JM; Pérez-Fidalgo JA; Ribas G; Burgués O; Mongort C; Alonso E; Ibarrola-Villava M; Bermejo B; Martínez MT; Cervantes A; Lluch A
Breast Cancer Res Treat; 2016 Nov; 160(1):69-77. PubMed ID: 27628192
[TBL] [Abstract][Full Text] [Related]
38. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive genetic and functional characterization of IPH-926: a novel CDH1-null tumour cell line from human lobular breast cancer.
Christgen M; Bruchhardt H; Hadamitzky C; Rudolph C; Steinemann D; Gadzicki D; Hasemeier B; Römermann D; Focken T; Krech T; Ballmaier M; Schlegelberger B; Kreipe H; Lehmann U
J Pathol; 2009 Apr; 217(5):620-32. PubMed ID: 19191266
[TBL] [Abstract][Full Text] [Related]
40. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]